Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
Schulman
Claude
C
Department of Urology, University Clinics of Brussels, Erasme Hospital, Brussels, Belgium. Claude.Schulman@ulb.ac.be
Alcaraz
Antonio
A
Berges
Richard
R
Montorsi
Francesco
F
Teillac
Pierre
P
Tombal
Bertrand
B
D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D032921:Consensus; D003692:Delayed-Action Preparations; D006801:Humans; D016729:Leuprolide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007986:Luteinizing Hormone / Q000819:agonists*; D008297:Male; D011364:Professional Practice; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; C493311:luprolide acetate gel depot; D013739:Testosterone; D007986:Luteinizing Hormone; D017430:Prostate-Specific Antigen; D016729:Leuprolide